research use only

Solithromycin Bacterial inhibitor

Cat.No.S5268

Solithromycin (CEM-101, OP-1068), belonging to the well-known class of macrolide antibiotics that also includes azithromycin, is a potent bacterial protein synthesis inhibitor.
Solithromycin Bacterial inhibitor Chemical Structure

Chemical Structure

Molecular Weight: 845.01

Quality Control

Chemical Information, Storage & Stability

Molecular Weight 845.01 Formula

C43H65FN6O10

Storage (From the date of receipt)
CAS No. 760981-83-7 -- Storage of Stock Solutions

Synonyms CEM-101, OP-1068 Smiles CCC1C2(C(C(C(=O)C(CC(C(C(C(=O)C(C(=O)O1)(C)F)C)OC3C(C(CC(O3)C)N(C)C)O)(C)OC)C)C)N(C(=O)O2)CCCCN4C=C(N=N4)C5=CC(=CC=C5)N)C

Solubility

In vitro
Batch:

DMSO : 100 mg/mL (118.34 mM)
(Moisture-contaminated DMSO may reduce solubility. Use fresh, anhydrous DMSO.)

Ethanol : 25 mg/mL

Water : Insoluble

Molarity Calculator

Mass Concentration Volume Molecular Weight

In vivo
Batch:

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg
g
μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO
%
% Tween 80
% ddH2O
% DMSO
+
%

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Mechanism of Action

Clinical Trial Information

(data from https://clinicaltrials.gov, updated on 2024-05-22)

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT02628769 Terminated
Pulmonary Disease Chronic Obstructive
Imperial College London|Melinta Therapeutics Inc.
July 2015 Phase 2
NCT02348424 Completed
Gonorrhoea
National Institute of Allergy and Infectious Diseases (NIAID)
May 5 2015 Phase 1
NCT02268279 Completed
Bacterial Infection
Melinta Therapeutics Inc.|Department of Health and Human Services
January 2015 Phase 1
NCT02210325 Completed
Uncomplicated Urogenital Gonorrhea
Melinta Therapeutics Inc.|National Institute of Allergy and Infectious Diseases (NIAID)
August 2014 Phase 3
NCT01966055 Completed
Bacterial Infections
Melinta Therapeutics Inc.|Department of Health and Human Services
December 2013 Phase 1
NCT01591447 Completed
Uncomplicated Urogenital Gonorrhea
Melinta Therapeutics Inc.
May 2012 Phase 2

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.